Connect with us

Biotechnology

4 Biotech Stocks Taking Center Stage With Cancer-Fighting Treatments

Joe Samuel

Published

on

biotech stocks to watch

Investors Turn Their Attention To Stocks Looking To Lead The Way In Immunotherapies

Cancer has been one of the most destructive diseases for more than a century. Even now, a foolproof treatment for the many variants of cancer has not been created. However, that doesn’t mean that a range of companies aren’t spending billions of dollars on cancer research. If a company does come up with a credible cancer drug, it’s likely to be a big focus of the market. Here are several biotech stocks to watch in their quest to become leaders in immunotherapy.

GT Biopharma (GTBP)

Early, clinical stage companies like GT Biopharma (GTBP) present a number of value propositions for investors.  Though many of these companies can hold higher risk due to lack of revenues, incurring high levels of expenses due to research, development, and SG&A, they can also offer higher rewards if early successes are realized.

So far, GT Biopharma has come up favorably with respect to trial results on more than just one of its therapies in the pipeline.  Certainly, though the most recent developments with it OXS-1550 could deliver the most near term opportunities.

The company’s previous announcement that it would be working with a “major pharmaceutical company” may suggest that GT Biopharma (GTBP) could be positioning itself for a strategic move at the very least. 

Though the “major company” was left nameless, we can infer from comments made by Dr. Daniel Vallera that the “multi-billion dollar oncology drug” is ibrutinib. The statement made in a company press release specifically stated, “We are very excited about our progress with GT’s OXS-1550 (DT2219) combined with ibrutinib, a potent small molecule Bruton Tyrosine Kinase (BTK) inhibitor which is already an established chemotherapeutic agent.  We believe combination therapies like these that kill cancer cells based on entirely different mechanisms are the future of cancer treatment.”

Knowing this, we can begin connecting dots to the companies linked to ibrutinib. Its trade name is Imbruvica and is a drug that was developed by Pharmacyclics and Janssen. 

Both Pharmacyclics and Janssen are subsidiaries of major pharmaceutical companies; Abbvie and Johnson & Johnson respectively.

Recent Progress With HIV Treatment Could Become A BIG Competitive Advantage Too. The company’s therapy showed that it could target HIV infected cells in the University of Minnesota’s preclinical testing. Not only that but in specific tests, data showed that HIV-infected targets that express the HIV envelope on their surface could actually be eliminated! Click Here To Read More

Guardant Health (GH)

Guardant Health (GH) is a company that has made a name for itself in two highly important segments within the cancer treatment industry. The company is involved in producing a liquid biopsy. It is also involved in detecting whether cancer is in danger of repapering in a patient or whether an individual is at risk of developing.

The first market is valued at $15 billion, while the market for the second focus is valued at $18 billion. Additionally, its LUNAR DNA Test product detects cancer at an early stage. It has also given the company a huge boost. The stock has soared by as much as 103% in 2019. That is significantly more than the 2.3% in the industry as well.

Illumina (ILMN)

Illumina (ILMN) is another company that holds a lot of promise. It provides researchers with sequencing and that in turn helps in the fight against cancer substantially. The sequencing products made by the company help researchers in understanding the reasons behind the onset of cancer and the company’s products are also used to diagnostic testing purposes.

The demand for its products have been rising steadily and the company has also completed strategic partnerships to further boost its business. Some of Illumina’s partners include Sysmex, Bristol-Myers Squibb and Loxo Oncology.

Exact Sciences Corporation (EXAS)

As if well known by now, colon cancer is one of the dangerous forms of the disease and accounts for many deaths a year. Patients need to go for colonoscopy in order to get the treatment for colon cancer but it is highly expensive.

Exact Sciences Corporation (EXAS) has come up with a product named Cologuard that is an alternative to colonoscopy and the product has proven to be successful ever since its launch back in 2014. In 2018 alone, Cologuard accounted for $454 million in revenues for the company and in 2019, as many as 334000 people have been tested already.

Q1 2019 revenues went up by a whopping 79% year on year. In addition to that, it is the only FDA approved product of its kind and the company has also entered into a partnership with major drug manufacturer Pfizer. The deal will be in place until 2021.

stock_price_health
Pursuant to an agreement between MIDAM VENTURES, LLC and GT Biopharma, Midam was hired for a period from 06/07/2019 – 7/07/2019 to publicly disseminate information about GT Biopharma including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of GT Biopharma in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer.

Continue Reading
Click to comment

Biotechnology

Biotech Stocks To Watch In June: Cara Therapeutics (CARA) & Intellia Therapeutics (NTLA)

Jon Phillip

Published

on

biotech stocks to watch june

Among biotech companies, the competition between Cara Therapeutics Inc (CARA) and Intellia Therapeutics Inc (NTLA) has been an intriguing one. The two companies had been on the same level as far as the market cap goes during most of the year so far.

But Cara has now pulled ahead by as much as $150 million following positive data from its lead product candidate. That being said, it is also important to keep in mind that if an investor is looking at a long term investment, then the disparity in market cap between the two companies is a minor. Here’s a look at the pros and cons of Cara and Intellia.

Cara Therapeutics (CARA)

Cara Therapeutics is currently on the rise. Its lead product candidate Korsuva injection delivered highly encouraging results in its Phase 3 trial. It’s now believed that it would not be long before Cara has its first product on the market.

[NEXT] Biotech Companies Are Driving Innovation…See Which Ones

It is meant for the treatment of moderate-to-severe chronic kidney disease-associated pruritus. According to reports, the results were great. Another late-stage test is going to be conducted soon. The results could be announced by the end of this year. If Korsuve is approved, then it will be marketed by Fresenius Medical Care and Vifor Pharma Group.

Cara has entered joint ventures with those companies to market the product in the United States, Japan, and South Korea. An oral version of Korsuva is also in the pipeline and could prove to be another important development.

Intellia Therapeutics (NTLA)

Intellia Therapeutics (INTA) is involved in creating CRISPR gene editing therapies. It is a segment that has a lot of promise in the future. Even though the company is some years away from having anything on the market, the promise of gene editing therapy is exciting. So much so that Intellia has already found partners in big-ticket firms like Regeneron and Novartis.

Intellia is expected to file for FDA approval for the clinical study into its lead product NLTA-2001 in 2020. It is meant for the treatment of transthyretin amyloidosis, an uncommon genetic disease. Studies into the products have proven to be promising so far. The company is also working on a product to treat myeloid leukemia.

Now when it comes to choosing between Cara and Intellia, experts believe that the former could a better company. It’s already on the verge of having an approved product on the market. Intellia, on the other hand, is likely to be some years away from winning approval.

Continue Reading

Biotechnology

Is Palatin Technologies (PTN) A Penny Stock To Buy Or Sell?

Joe Samuel

Published

on

Will Shares Of Palatin Technologies (PTN) Head Higher As Biotech Stocks Rally This Month?

Biotech stocks are rallying this month.  Despite the “pop and drop” this sector saw earlier in the year, June has been a big month for biotechnology companies and people investing in this sector. 

IBB ETF chart

In fact, the iShares Trust Biotechnology ETF (IBB) has climbed by more than 8% since the start of June. This sector has been famous for producing volatile returns for investors. Furthermore, biotech penny stocks have increased that potential.

Palatin Technologies (PTN) Is A Biotech Penny Stock To Watch

One of the best performing penny stocks in the biotechnology sector this month has been Palatin Technologies Inc. (PTN). On January 2, this penny stock opened the year at $0.71 and has seen a 2019 high of $1.74. What’s more is that even though PTN stock has consolidated, it has continued to trade above $1.20.

So what’s all the excitement about? Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

The company’s main strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.

[New Research] Big Investments Are Signaling The Green Light For A ‘Hot Market’ With Cancer-Fighting Stocks

The recent excitement seems to have started in April after the company reported positive top-line results of its oral clinical study of PL-8177. The treatment is designed to address ulcerative colitis and other inflammatory bowel diseases.

“The main objective of the study was to demonstrate release of polymer-bound PL-8177 in the lower gastrointestinal tract after oral administration. Top line data showed favorable pharmacokinetics, and demonstrated PL-8177 was released in the lower gastrointestinal tract, supporting oral administration of PL-8177 using the delayed release polymer formulation.”

New Milestones From Palatine Technologies (PTN) Triggers New Highs

After hitting new highs on May 17th after posting quarterly earnings, shares of PTN stock have consolidated. Regardless, the company continues to progress. Earlier this month the company obtained orphan drug designation for PL-8177. Yes, this is the same one that I talked about above when the company received positive topline results earlier in the year.

Why is orphan drug designation important? This is a good question especially if you’re newer to biotech penny stocks or biopharmaceutical stocks, in general. In the exact words of the FDA:

“The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation (or sometimes “orphanstatus”).”

Essentially it gives companies incentives above and beyond competitors. These incentives include a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for 7 years of marketing exclusivity. The obvious response would be favorable, which has been seen in the market over the past few trading sessions.

Dr. Carl Spana, President and Chief Executive Officer of Palatin Technologies, said in a press release, “Unlike corticosteroids, immunosuppressive agents, and biological therapies targeting specific cytokines or receptors, melanocortin receptor 1 peptides work to resolve chronic inflammations and restore normal immune function. We look forward to initiating clinical trials with PL-8177 for non-infectious uveitis, a high medical need disease with limited treatment options.”

But Here’s Why Palatin Might Be Set For More Excitement

It’s all about sex drive. You read that right. And something that hasn’t really been fully publicized is this “big FDA date.” You see on June 23rd, the application for Vyleesi (bremelanotide), a drug developed by Palatin and licensed to AMAG Pharmaceuticals (AMAG) will be up for review by the FDA as a New Drug.

Vyleesi is a novel melanocortin 4 receptor agonist under evaluation for restoring a natural sexual desire in premenopausal women with HSDD. Think of this like female Viagra. Will this become the sexiest biotech penny stock this month or will stock traders get blue balled?

Like This Article? Check Out: Small Cap Biotech Stocks See Boost From Large Cap M&A

Continue Reading

Biotechnology

Healthcare Penny Stocks To Watch: Driven Deliveries Inc. (DRVD), Biocept Inc. (BIOC), Cesca Therapeutics Inc. (KOOL), PhaseBio Pharmaceuticals Inc. (PHAS)

Joe Samuel

Published

on

Healthcare penny stocks tend to be the largest movers among other penny stocks. This is mainly due to the amount of news they release. For example, any development in treatment becomes a news catalyst, which happens more often than other news.

Driven Deliveries Inc. (DRVD)

Driven Deliveries Inc. (DRVD) is primarily a technology company so why include it with other healthcare penny stocks? It is included because of what Driven’s technology is capable of, delivering medical and recreational marijuana. Medical marijuana legality is sweeping across the US which is only expanding the future demand for the services Driven provides.

More studies are beginning to show the positive effects of marijuana in relation to stress and pain relief. These studies make Driven’s recent announcement way more important. Driven revealed a partnership with Pure Ratios, a company selling 96-hour pain relief CBD and THC patches. This product is the only of its kind as it bypasses the digestive process and is absorbed directly into the bloodstream.

[REPORT] One of the Only Public Cannabis Delivery Services in the United States…Here’s What To Know

Christian Schenk, CEO of Driven, stated, “We believe that our best-in-class delivery platform coupled with Pure Ratio’s proven popular brands will provide a strong synergistic relationship between the companies.  We look forward to expanding our customer base while increasing revenue and enhancing our overall brand recognition.  Management has already identified several similar popular brands that it intends to add to our platform in the near future.”

Biocept Inc (BIOC)

Biocept Inc (BIOC) is a healthcare company that uses liquid biopsy technology to assess several forms of cancer for physicians. Biocept has their own liquid biopsy platform known as Target SelectorTM which can analyze tumor markers.

Recently, Biocept announced a new Target SelectorTM platform for breast cancer. It is Biocept’s second tumor-specific panel and will help target the second leading cause of death for women. In addition, Biocept’s platform allows medical personnel to evaluate patients with metastatic breast cancer which is usually very difficult. This news has brought strong volume and a 11% pre-market move.

Cesca Therapeutics Inc. (KOOL)

Cesca Therapeutics Inc. (KOOL) is a medical device healthcare company for cell-based therapeutics. Cesca is an affiliate of the BoyaLife Group which is based out of China. Cesca is using its AutoXpress platform to meet the needs regarding cardio, vascular, and immune diseases.

One of Cesca’s subsidiaries, ThermoGenesis, recently received approval for its Next-Gen AXP II System for cord blood processing. The AXP II System allows for the processing and storage of hematopoietic stem call concentrates. Also, multiple cord blood units can be processed in one centrifuge. Thanks to this approval, Cesca’s stock increased by more than 40%.

PhaseBio Pharmaceuticals Inc. (PHAS)

PhaseBio Pharmaceuticals Inc. (PHAS) is a biopharmaceutical company whose primary goal is creating and selling treatments to orphan diseases. Their primary drug is called PB2452 which reverses antiplatelet activity. PB2452 recently received positive preliminary results from Phase 2a clinical trial. These results pushed the stock from $12.19 to $14.08 on June 18th.

“If approved, PB2452 could help address these critical unmet medical needs by enhancing the safety profile of ticagrelor, which has the potential to become the only antiplatelet therapy on the market with a specific reversal agent. We look forward to reporting full results from the Phase 2a trial at an upcoming medical congress.”

John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio

stock_price_weed
Disclaimer: Pursuant to an agreement between MIDAM VENTURES, LLC and a third party, Data Marketing Solutions Inc., Midam was hired for a period from 04/22/2018 – 5/22/2019 to publicly disseminate information about Driven Deliveries Inc. including on the Website and other media including Facebook and Twitter. We were paid $50,000 (CASH) for & were paid “0” shares of restricted common shares. We may buy or sell additional shares of Driven Deliveries Inc. Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click Here For Full Disclaimer

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


We keep all user information pricate & promise to never spam.*

Privacy Policy

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com